US Bancorp
PRQR icon

US Bancorp’s ProQR Therapeutics PRQR Stock Holding History

US Bancorp’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,214
Closed -$5.87K – 4331
2024
Q4 		$5.87K Buy
+2,214
New +$7.03K ﹤0.01% 3600
2022
Q2 		– Sell
-5,087
Closed -$5K – 4190
2022
Q1 		$5K Sell
5,087
-342
-6% -$1.15K ﹤0.01% 3621
2021
Q4 		$43K Buy
5,429
+1,736
+47% +$13.2K ﹤0.01% 2735
2021
Q3 		$31K Buy
3,693
+2,030
+122% +$13.3K ﹤0.01% 2896
2021
Q2 		$11K Buy
+1,663
New +$10.7K ﹤0.01% 3373
2020
Q2 		– Sell
-818
Closed -$5K – 3838
2020
Q1 		$5K Buy
818
+572
+233% +$4.39K ﹤0.01% 3264
2019
Q4 		$2K Buy
+246
New +$1.92K ﹤0.01% 3494

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

US Bancorp's PRQR Position: Q1 2025 in Review

US Bancorp sold out of ProQR Therapeutics (PRQR) in Q1 2025, closing a stake of 2,214 shares — an estimated $5.87K sold.

US Bancorp first reported a position in PRQR in Q4 2019 and held it in 7 quarters. The position peaked at $43K in Q4 2021. 65 funds tracked by Wall St. Rank hold PRQR as of Q1 2025.

  • US Bancorp reported no remaining ProQR Therapeutics position as of Q1 2025 after selling out during the quarter.
  • US Bancorp sold 2,214 ProQR Therapeutics shares in Q1 2025, an estimated $5.87K.
  • US Bancorp first reported a position in ProQR Therapeutics in Q4 2019 and held it in 7 quarters.
  • US Bancorp's ProQR Therapeutics position peaked at $43K in Q4 2021.
  • 65 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2025.

Based on US Bancorp's 13F filing for Q1 2025, filed 8 May 2025.